Sinopharm needs trial results to decide if Covid-19 shot needs booster: Executive
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Monday
February 06, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
MONDAY, FEBRUARY 06, 2023
Sinopharm needs trial results to decide if Covid-19 shot needs booster: Executive

Coronavirus chronicle

Reuters
28 March, 2021, 02:10 pm
Last modified: 28 March, 2021, 02:35 pm

Related News

  • Some Omicron sub-variants escaping antibodies from Sinopharm shot
  • Sinopharm protein-based booster stronger against Omicron than earlier shot -study
  • UAE approves Sinopharm's protein-based vaccine
  • Local production of Sinopharm vaccine uncertain
  • Sinopharm Covid-19 booster weaker against Omicron - study

Sinopharm needs trial results to decide if Covid-19 shot needs booster: Executive

"Antibodies triggered by two Covid-19 vaccine products from Sinopharm both have good neutralising effect on variants found in Britain and South Africa"

Reuters
28 March, 2021, 02:10 pm
Last modified: 28 March, 2021, 02:35 pm
A booth displaying a coronavirus vaccine candidate from China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the Covid-19 outbreak, in Beijing, China September 4, 2020. REUTERS/Tingshu Wang
A booth displaying a coronavirus vaccine candidate from China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the Covid-19 outbreak, in Beijing, China September 4, 2020. REUTERS/Tingshu Wang

China National Pharmaceutical Group (Sinopharm) will need to assess results from overseas Phase III clinical trials to decide whether its two-shot Covid-19 vaccine should be followed by a booster shot, a company executive said on Sunday.

Regulators and vaccine developers are looking at whether booster doses are necessary amid concerns that emerging variants of the new coronavirus might weaken protection of vaccines designed against older strains.

Antibodies triggered by Sinopharm's regular vaccines last about six months based on clinical trial data, Zhang Yuntao, vice president at China National Biotec Group (CNBG), an affiliate of Sinopharm, said on Sunday.

"The preliminary results so far showed that the booster vaccination can effectively increase the neutralizing antibody titer and antibody persistence, and also effectively improve the vaccine's ability to resist mutations," Zhang said at a news conference.

"Is a booster shot needed? When will the booster be given? The answer should be based on the results of future phase III clinical studies," Zhang said.

Antibodies triggered by two Covid-19 vaccine products from Sinopharm both have "pretty good" neutralising effect on variants found in Britain and South Africa, Zhang told a news conference, citing results from lab tests using blood samples taken from clinical trial participants.

Lab testing was ongoing for variants found in Brazil and Zimbabwe, Zhang said.

Sinopharm Covid-19 Vaccine / Sinopharm vaccine / Sinopharm

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A man walks past by a collapsed building after an earthquake in Malatya, Turkey February 6, 2023. Depo Photos via REUTERS
    Over 350 dead, many trapped under rubble as 7.9 magnitude quake rocks Turkey and Syria
  • LC issues lead to severe shortage of surgical equipment
    LC issues lead to severe shortage of surgical equipment
  • How govt is losing dividend from six listed firms
    How govt is losing dividend from six listed firms

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong says 'hello' to woo back visitors after Covid
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • Some Omicron sub-variants escaping antibodies from Sinopharm shot
  • Sinopharm protein-based booster stronger against Omicron than earlier shot -study
  • UAE approves Sinopharm's protein-based vaccine
  • Local production of Sinopharm vaccine uncertain
  • Sinopharm Covid-19 booster weaker against Omicron - study

Features

Photo: Collected

Get your partner a lovely present this Valentine's Day

2h | Brands
Pottery Wheel Craft Kit: A creative outlet for little hands

Pottery Wheel Craft Kit: A creative outlet for little hands

2h | Brands
Say it with Colours

Say it with Colours

1d | Mode
Photo: Courtesy

From 'Made in Bangladesh' to 'Designed in Bangladesh'

1d | Panorama

More Videos from TBS

Stage plays are going on in the digital age

Stage plays are going on in the digital age

1h | TBS Stories
Why does all the versatile roles go to Jisan?

Why does all the versatile roles go to Jisan?

1h | TBS Entertainment
ICB to withdraw Padma Bank Investment as return

ICB to withdraw Padma Bank Investment as return

18h | TBS Insight
Kiara Advani & Sidharth Malhotra's Wedding Update

Kiara Advani & Sidharth Malhotra's Wedding Update

18h | TBS Entertainment

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

3
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

4
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

5
Photo: Collected
Startups

ShopUp secures $30m debt financing to boost expansion, supply chain

6
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]